13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neurobiology
The field of neurobiology is essential for understanding the complexities of the nervous system and its role in behavior, cognition, and disease. By investigating the molecular and genetic foundations of brain activity, neurobiologists aim to uncover the causes of various neurological disorders, from epilepsy to neurodegenerative diseases. The interactions between neurons, glial cells, and their microenvironment are key areas of focus, with research revealing how these cellular networks influence brain development, plasticity, and repair. Neurobiology also explores how environmental factors, such as stress and toxins, can impact brain function and contribute to psychiatric and neurological conditions. The rapid advancement of technologies such as brain imaging and CRISPR gene editing is accelerating discoveries in this field, providing new insights into both healthy brain function and disease mechanisms.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States